Matches in Wikidata for { <http://www.wikidata.org/entity/Q67124250> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q67124250 description "clinical trial" @default.
- Q67124250 description "ensayu clínicu" @default.
- Q67124250 description "klinisch onderzoek" @default.
- Q67124250 description "клінічне випробування" @default.
- Q67124250 name "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 name "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 type Item @default.
- Q67124250 label "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 label "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 prefLabel "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 prefLabel "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 P1050 Q67124250-52F11A17-2716-4609-8E1A-50802B5CFC6B @default.
- Q67124250 P1132 Q67124250-215E400D-6299-490E-ADE5-3B27D0712200 @default.
- Q67124250 P1476 Q67124250-C8D5D3DD-CAE1-431C-84D4-60DC1B60B399 @default.
- Q67124250 P2899 Q67124250-BCF72C30-D5A7-430F-A20A-C35367B9E4B2 @default.
- Q67124250 P3098 Q67124250-3073227F-036F-466C-BFBA-4FBDB5BD79C4 @default.
- Q67124250 P31 Q67124250-BEFDFAC2-F07C-4BA2-B35E-C49E5941DF2F @default.
- Q67124250 P4844 Q67124250-6D3EE648-C889-4DFB-A4D4-1D17E61E9B7C @default.
- Q67124250 P580 Q67124250-14D449DC-F064-4683-BBBD-0B133C1E0ABA @default.
- Q67124250 P582 Q67124250-2E0A6E91-FCE1-4D08-8535-6EE3A020091C @default.
- Q67124250 P6099 Q67124250-5CE1B80A-E872-4044-BD81-8762DCD76206 @default.
- Q67124250 P8363 Q67124250-9BBD2714-60C0-434E-BC5C-F0AF835F43EC @default.
- Q67124250 P1050 Q33525 @default.
- Q67124250 P1132 "+42" @default.
- Q67124250 P1476 "A Phase 1b Study of M6620 in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer" @default.
- Q67124250 P2899 "+18" @default.
- Q67124250 P3098 "NCT04052555" @default.
- Q67124250 P31 Q30612 @default.
- Q67124250 P4844 Q26963 @default.
- Q67124250 P580 "2019-11-22T00:00:00Z" @default.
- Q67124250 P582 "2020-10-31T00:00:00Z" @default.
- Q67124250 P6099 Q5452194 @default.
- Q67124250 P8363 Q78089383 @default.